Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Published:2017-05-09 Issue:4 Volume:178 Page:571-582
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kumar Shaji¹^ORCID,Moreau Philippe²^ORCID,Hari Parameswaran³,Mateos Maria-Victoria⁴,Ludwig Heinz⁵,Shustik Chaim⁶,Masszi Tamas⁷,Spencer Andrew⁸,Hájek Roman⁹,Romeril Kenneth¹⁰,Avivi Irit¹¹,Liberati Anna M.¹²,Minnema Monique C.¹³,Einsele Hermann¹⁴^ORCID,Lonial Sagar¹⁵,Berg Deborah¹⁶,Lin Jianchang¹⁶,Gupta Neeraj¹⁶^ORCID,Esseltine Dixie-Lee¹⁶,Richardson Paul G.¹⁷

Affiliation:

1. Division of Hematology; Mayo Clinic; Rochester MN USA

2. University Hospital Hôtel Dieu; Nantes France

3. Division of Hematology and Oncology; Froedtert Hospital and the Medical College of Wisconsin; Milwaukee WI USA

4. Servicio de Hematología; Hospital Universitario de Salamanca; Salamanca Spain

5. Wilhelminenspital der Stadt Wien; Vienna Austria

6. McGill University Health Center; Royal Victoria Hospital; Montreal Canada

7. Department of Haematology and Stem Cell Transplantation; St István and St László Hospital; Semmelweis University Budapest Hungary

8. Alfred Health-Monash University; Melbourne Australia

9. Department of Haematooncology; University Hospital Ostrava; Ostrava Czech Republic

10. Wellington Blood and Cancer Centre; Wellington Regional Hospital; Wellington New Zealand

11. Department of Haematology and Bone Marrow Transplantation; Tel Aviv Medical Centre; Tel Aviv Israel

12. University of Perugia; SC Oncoematologia AO S. Maria di Terni; Terni Italy

13. Department of Haematology; UMC Utrecht Cancer Centre; Utrecht The Netherlands

14. Universitätsklinik Würzburg; Medizinische Klinik und Poliklinik II; Würzburg Germany

15. Department of Hematology and Medical Oncology; Winship Cancer Institute; Emory University School of Medicine; Atlanta GA USA

16. Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge MA USA

17. Dana-Farber Cancer Institute; Boston MA USA

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14733/fullpdf

Reference50 articles.

1. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib;Atrash;Blood Cancer Journal,2015

2. Good publication practice for communicating company-sponsored medical research: GPP3;Battisti;Annals of Internal Medicine,2015

3. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life;Baz;Supportive Care in Cancer,2015

4. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma;Benboubker;New England Journal of Medicine,2014

5. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma;Chen;British Journal of Haematology,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis;European Journal of Haematology;2024-08-26

2. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group;Cancers;2024-02-29

3. Sars-CoV-2 infection in different hematological patients;Management, Body Systems, and Case Studies in COVID-19;2024

4. Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study;Annals of Hematology;2023-06-10

5. An update on the safety of ixazomib for the treatment of multiple myeloma;Expert Opinion on Drug Safety;2022-09-02